CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new mucosal adjuvants to enhance vaccine efficacy against infectious diseases. It investigates the mechanisms of action of Toll-like receptor agonists, particularly flagellin, to improve immune responses at the site of infection, aiming for safer and more effective nasal or oral vacci…
The development of new vaccines against infectious diseases is a major worldwide public health objective.
Despite the availability of antimicrobial therapies, vaccines still constitute the most effective means of controlling infections.
Adjuvants are crucial for increasing the onset, magnitude, diversity and memory of immune responses to vaccines.
Whereas a range of adjuvants is available for conventional vaccination routes, there are currently no mucosal adjuvants for promoting the neutralizati…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
